Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Core Insights - Targeted protein degradation is an emerging field in drug development, with over 10 years of experience from the company [1] - The company is based in San Francisco and leverages scientific research from UCSF and Berkeley [1] - Targeted protein degraders are small molecules that can be taken orally to remove disease-causing proteins from cells [2] Industry Context - The development of targeted protein degradation is positioned alongside major breakthroughs in drug development, such as antibodies and nucleic acid-based therapies [2] - The primary goal of therapeutics has been to specifically target disease-causing proteins, which is now achievable through targeted protein degradation [2]